A. Spinou (London, United Kingdom), M. Shteinberg (Haifa, Israel)
Salivary SLPI and disease severity in bronchiectasis
L. Perea (Barcelona, Spain), E. Cantó (Barcelona, Spain), J. Giner (Barcelona, Spain), S. Aliberti (Milan, Italy), J. Chalmers (Dundee, United Kingdom), S. Vidal (Barcelona, Spain), O. Sibila (Barcelona, Spain)
|   |
Proteinase-3 as a biomarker of exacerbations in bronchiectasis.
H. Abo-Leyah (Dundee, United Kingdom), Y. Gao (Dundee, United Kingdom), H. Richardson (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), A. Dicker (Dundee, United Kingdom), K. Moffitt (Belfast, United Kingdom), A. Shoemark (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
Bronchiectasis: prevalance of asthma diagnosis and asthma-associated factors
T. van der Veer (Rotterdam, Netherlands), M. Bakker (Rotterdam, Netherlands), L. Kamphuis (Rotterdam, Netherlands), A. Dubois (Rotterdam, Netherlands), R. Hoek (Rotterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), M. Van Der Eerden (Rotterdam, Netherlands)
| |
Alpha-1 antitrypsin deficiency in patients with bronchiectasis: data from the European Bronchiectasis Registry EMBARC
M. Loebinger (London, United Kingdom), S. Aliberti (Milan, Italy), R. Menendez (Valencia, Spain), F. Blasi (Milan, Italy), P. Burgel (Paris, France), F. Ringshausen (Hannover, Germany), M. Trautmann (Barcelona, Spain), A. Davis (Barcelona, Spain), A. De Soyza (Newcastle, United Kingdom), M. Shteinberg (Haifa, Israel), A. Shoemark (Dundee, United Kingdom), J. Altenburg (Amsterdam, Netherlands), J. Chalmers (Dundee, United Kingdom), M. Vendrell (Girona, Spain), E. Polverino (Barcelona, Spain), S. Skrgat (Golnik, Slovenia), M. Van Der Eerden (Rotterdam, Netherlands), W. Boersma (Alkmaar, Netherlands), O. Sibila (Barcelona, Spain), M. Mcdonnell (Galway, Ireland), L. Maiz (Madrid , Spain), P. Kauppi (Helsinki, Finland), V. Botnaru (Chisinau, Republic of Moldova), E. Van Braeckel (Gent, Belgium), N. Lorent (Leuven, Belgium), J. Rademacher (Hannover, Germany), C. Haworth (Cambridge, United Kingdom), K. Dimakou (Athens, Greece), A. Torres (Barcelona, Spain), T. Welte (Hannover, Germany), S. Elborn (Belfast, United Kingdom), P. Goeminne (Belgium, Belgium)
| |
Factors associated with one-year mortality in hospitalized patients with exacerbation of bronchiectasis.
G. Scioscia (Foggia, Italy), R. Amaro (Barcelona, Spain), V. Alcaraz-Serrano (Barcelona, Spain), A. Gabarrus (Barcelona, Spain), L. Fernandez-Barat (Barcelona, Spain), P. Oscanoa Huamán (Barcelona, Spain), R. Menendez (Valencia, Spain), R. Mendez (Valencia, Spain), M. Foschino Barbaro (Foggia, Italy), A. Torres (Barcelona, Spain)
| |
Heterogeneity of treatment response in bronchiectasis clinical trials
O. Sibila (Barcelona, Spain), E. Laserna (Mollet del Valles, Spain), A. Shoemark (Dundee, United Kingdom), D. Bilton (London, United Kingdom), M. Crichton (Dundee, United Kingdom), A. De Soyza (Newcastle, United Kingdom), W. Boersma (Alkmaar, Netherlands), J. Altenburg (Amsterdam, Netherlands), J. Chalmers (Dundee, United Kingdom)
| |
Results of Tobramycin inhalation therapy in patients with noncystic fibrosis bronchiectasis with Pseudomonas Aeruginosa colonization: Real Life Management
E. Tanriverdi (Istanbul, Turkey), B. Yildirim (Istanbul, Turkey), S. Gul (Istanbul, Turkey), E. Ugur Chousein (Istanbul, Turkey), D. Turan (Istanbul, Turkey), H. Cinarka (Istanbul, Turkey), M. Ozgul (Istanbul, Turkey), E. Cetinkaya (Istanbul, Turkey)
| |
Sex related differences in aetiology, severity and quality of life in bronchiectasis: data from the EMBARC, EMBARC-India and Australian bronchiectasis registries
A. Shoemark (Dundee (Angus), United Kingdom), S. Finch (Dundee (Angus), United Kingdom), A. Torres (Dundee (Angus), United Kingdom), S. Elborn (Dundee (Angus), United Kingdom), F. Ringhausen (Dundee (Angus), United Kingdom), A. De Soyza (Dundee (Angus), United Kingdom), S. Aliberti (Dundee (Angus), United Kingdom), F. Blasi (Dundee (Angus), United Kingdom), K. Dimakou (Dundee (Angus), United Kingdom), C. Haworth (Dundee (Angus), United Kingdom), A. Hill (Dundee (Angus), United Kingdom), M. Loebinger (Dundee (Angus), United Kingdom), M. Vendrell (Dundee (Angus), United Kingdom), T. Welte (Dundee (Angus), United Kingdom), R. Wilson (Dundee (Angus), United Kingdom), M. Crichton (Dundee (Angus), United Kingdom), P. Goeminne (Dundee (Angus), United Kingdom), P. Burgel (Dundee (Angus), United Kingdom), E. Polverino (Dundee (Angus), United Kingdom), R. Dhar (Kolkata, India), S. Singh (Kolkata, India), D. Talwar (Kolkata, India), M. Mohan (Kolkata, India), S. Kant Tripathi (Kolkata, India), . Swarnakar (Kolkata, India), S. Trivedi (Kolkata, India), S. Rajagopala (Kolkata, India), G. D'Souza (Kolkata, India), A. Padmanabhan (Kolkata, India), B. Archana (Kolkata, India), P. Mahesh (Kolkata, India), B. Ghewade (Kolkata, India), G. Nair (Kolkata, India), A. Jindal (Kolkata, India), G. Jayadevappa (Kolkata, India), H. Sawhney (Kolkata, India), K. Ranjan Sarmah (Kolkata, India), K. Saha (Kolkata, India), S. Anantharaj (Kolkata, India), A. Khanna (Kolkata, India), S. Gami (Kolkata, India), A. Shah (Kolkata, India), A. Shah (Kolkata, India), N. Dutt (Kolkata, India), H. Garg (Kolkata, India), S. Vyas (Kolkata, India), K. Venugopal (Kolkata, India), R. Prasad (Kolkata, India), A. Naveed M (Kolkata, India), S. Sharma (Kolkata, India), S. Karmakar (Kolkata, India), S. Salvi (KolkataDundee (Angus), India), R. Thomson (Sydney, Australia), D. Smith (Sydney, Australia), J. Waring (Sydney, Australia), L. Jayaram (Sydney, Australia), L. Burr (Sydney, Australia), C. Wong (Sydney, Australia), P. King (Sydney, Australia), P. Middleton (Sydney, Australia), G. Waterer (Sydney, Australia), A. Chang (Sydney, Australia), C. Holmes-Liew (Sydney, Australia), S. Visser (Sydney, Australia), E. Salama (Sydney, Australia), L. Morgan (Sydney, Australia), J. Chalmers (Dundee, United Kingdom)
| |
Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study
Y. Gao (zhengzhou, China), M. Lonergan (Dundee, United Kingdom), H. Abo-Leyah (Dundee, United Kingdom), S. Aliberti (Milan, Italy), R. Menendez (Valencia, Spain), F. Blasi (Milan, Italy), P. Regis-Burgel (Paris, France), F. Ringshausen (Hannover, Germany), A. De Soyza (Newcastle, United Kingdom), M. Vendrell (Girona, Spain), E. Polverino (Barcelona, Spain), S. Skrgat (Golnik, Slovenia), M. Van Der Eerden (Rotterdam, Netherlands), W. Boersma (Alkmaar, Netherlands), O. Sibila (Barcelona, Spain), M. Mcdonnell (Galway, Ireland), P. Kauppi (Helsinki, Finland), V. Botnaru (Chisinau, Republic of Moldova), E. Van Braeckel (Ghent, Belgium), N. Lorent (Leuven, Belgium), J. Rademacher (Hannover, Germany), C. Haworth (Cambridge, United Kingdom), K. Dimakou (Athens, Greece), M. R Loebinger (London, United Kingdom), A. Torres (Barcelona, Spain), T. Welte (Hannover, Germany), J. Stuart Elborn (Belfast, United Kingdom), M. L Crichton (Dundee, United Kingdom), P. C Goeminne (Sint Niklaas, Belgium), M. Shteinberg (Haifa, Israel), A. Shoemark (Dundee, United Kingdom), J. Altenburg (Amsterdam, Netherlands), J. D Chalmers (Dundee, United Kingdom)
| |
Evaluation of Neutrophlil to Lymphocyte Ratio (NLR) in bronchiectasis exacerbation.
V. Georgakopoulou (Athens, Greece), K. Mantzouranis (Athens, Greece), D. Melemeni (Athens, Greece), G. Petsinis (Athens, Greece), D. Mermigkis (Athens, Greece), A. Lekkakou (Athens, Greece), E. Karakou (Athens, Greece), R. Chatzikyriakou (Athens, Greece), N. Trakas (Athens, Greece), X. Tsiafaki (Athens, Greece)
| |
What’s important for people with NTM? An EMBARC-ELF patient survey
M. Shteinberg (Haifa, Israel), J. Boyd (sheffield, United Kingdom), B. Harris (sheffield, United Kingdom), P. Goemmine (Leuven, Belgium), A. Shoemark (Dundee, United Kingdom), J. Altenburg (Amsterdam, Netherlands), T. Ruddy (Sheffield, United Kingdom), T. Welte (Hannover, Germany), F. Blasi (Milan, Italy), B. Crossley (Sheffield, United Kingdom), S. Aliberti (Milan, Italy), E. Lloyd (Sheffield, United Kingdom), E. Polverino (Barcelona, Spain), J. Chalmers (Dundee, United Kingdom)
| |
Clinical outcome of multiple nontuberculous mycobacteria infection among people with bronchiectasis in Taiwan: a cohort study
H. Huang (Taipei, Taiwan), C. Lin (Taipei, Taiwan), Y. Huang (Taipei, Taiwan), C. Yeh (Taipei, Taiwan), C. Wang (Taipei, Taiwan), H. Lin (Taipei, Taiwan)
| |
The level of MDA in BALF might reflect oxidative tissue damage in patients with mild MAC pulmonary disease.
S. Oh-Ishi (Naka-gun, Japan), K. Nemoto (Naka-gun, Japan), H. Oshima (Naka-gun, Japan), K. Kawashima (Naka-gun, Japan), Y. Yabuuchi (Naka-gun, Japan), T. Shimada (Naka-gun, Japan), Y. Kitaoka (Naka-gun, Japan), H. Hirano (Naka-gun, Japan), N. Arai (Naka-gun, Japan), K. Hyodo (Naka-gun, Japan), A. Nakazawa (Naka-gun, Japan), J. Kanazawa (Naka-gun, Japan), Y. Miura (Naka-gun, Japan), S. Usui (Naka-gun, Japan), K. Hayashihara (Naka-gun, Japan), S. Fukai (Naka-gun, Japan), T. Saito (Naka-gun, Japan)
| |
The difference of airway microbiota between nontuberculous mycobacteria lung disease and bronchiectasis
C. Shu (Taipei, Taiwan)
| |
Non-tuberculous mycobacteria: five year experience
M. Conceição (Viseu, Portugal), Â. Cunha (Viseu, Portugal), R. Ferro (Viseu, Portugal), S. Guerra (Viseu, Portugal), J. Correia (Viseu, Portugal), A. Reis (Viseu, Portugal), A. Torres (Viseu, Portugal)
| |